Ben Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ben Hu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Shenhang Yao
Department of Endocrinology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, 230011, People’s Republic of China
3 shared publicationsJunshun Chang
Department of Nuclear Medicine First Hospital of Shanxi Medical University 030001 Taiyuan Shanxi People's Republic of China
2 shared publicationsSuyun Yang
Department of Nuclear Medicine First Hospital of Shanxi Medical University 030001 Taiyuan Shanxi People's Republic of China
2 shared publicationsXiangxiang Shan
Department of Endocrinology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, People’s Republic of China
2 shared publications- Yan Wang
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China
2 shared publications - Yong Hong Cao
Department of Endocrinology, Hefei Hospital Affiliated to Anhui Medical University, The Second People’s Hospital of Hefei, China
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (8)
Artificial Intelligence-Assisted Intravascular Imaging in Percutaneous Coronary Intervention: Current Status and Advances
Over the past two decades, intravascular imaging (IVI) has been widely integrated into clinical practice. Unlike traditional angiography, IVI uses an intracoronary imaging catheter to generate high-resolution cross-sectional images of diseased coronary arteries, thereby facilitating lesion characterization. These detailed images enable more accurate guidance of percutaneous coronary intervention (PCI). The clinical utility of IVI is demonstrated across four key stages: preoperative lesion assessment, intraoperative procedural guidance, postoperative complication detection, and evaluation of stent optimization. Despite these benefits, interventionalists continue to face challenges in consistently acquiring and interpreting high-quality IVI data. The emergence of artificial intelligence (AI) offers a promising solution by enabling precise image recognition and automated quantitative analysis, thereby supporting efficient clinical decision-making and broadening the scope of IVI applications. This review aims to summarize recent research progress in AI-assisted IVI across the PCI process and discuss future directions to improve the intelligence and efficiency of intravascular imaging.
- 18 August 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (8)
Open AccessArtificial Intelligence-Assisted Intravascular Imaging in Percutaneous Coronary Intervention: Current Status and Advances
Over the past two decades, intravascular imaging (IVI) has been widely integrated into clinical practice. Unlike traditional angiography, IVI uses an intracoronary imaging catheter to generate high-resolution cross-sectional images of diseased coronary arteries, thereby facilitating lesion characterization. These detailed images enable more accurate guidance of percutaneous coronary intervention (PCI). The clinical utility of IVI is demonstrated across four key stages: preoperative lesion assessment, intraoperative procedural guidance, postoperative complication detection, and evaluation of stent optimization. Despite these benefits, interventionalists continue to face challenges in consistently acquiring and interpreting high-quality IVI data. The emergence of artificial intelligence (AI) offers a promising solution by enabling precise image recognition and automated quantitative analysis, thereby supporting efficient clinical decision-making and broadening the scope of IVI applications. This review aims to summarize recent research progress in AI-assisted IVI across the PCI process and discuss future directions to improve the intelligence and efficiency of intravascular imaging.
- Open Access
- 3 April 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (2) , 760-781
Global Co-occurrence Patterns of Cancer and Cardiovascular Disease: A Comprehensive Analysis Based on the Global Burden of Disease Study 2021
Introduction: Cardiovascular disease (CVD) and neoplasms are the two leading causes of death worldwide. Previous research has predominantly addressed these conditions separately or focused on specific regions. We aimed to characterize the global co-occurrence pattern of CVD and neoplasms from spatial and temporal perspectives and identify corresponding risk factors across different epidemiological contexts. Material and methods: Using GBD 2021 data, we extracted age-standardized disability-adjusted life years (DALYs) rates of CVD and neoplasms and modifiable risk factor exposure from 204 countries and territories (1990-2021). We identified four epidemiological patterns: low-burden, neoplasms-dominant, CVD-dominant, and dual-burden regions. We calculated population attributable fractions (PAF) and integrated machine learning with SHAP values to distinguish intervention priorities. Average annual percentage changes (AAPC) evaluated temporal trends. Results: Each pattern comprised 50-52 countries. Spatial distribution overlapped with socioeconomic development stages and risk factor exposure. Temporal analysis revealed widening global inequality: low-burden regions achieved 3-4% annual reductions while dual-burden regions experienced increasing burden, creating a 5.8 percentage point gap. High systolic blood pressure was the universal dominant CVD risk factor, accounting for 49.7% of global burden (49.2-52.4% across patterns). For neoplasms, smoking contributed 18.5% globally but varied dramatically by pattern (10.4-23.4%). Modifiable risk factors' specific combinations greatly influenced global disparities. Conclusions: The co-occurrence of CVD and neoplasms represents interconnected manifestations of different epidemiological transition stages, with concerning divergence between regions. Interventions targeting hypertension control and tobacco cessation, combined with pattern-specific strategies, can fundamentally reduce global disease burden.
- 3 April 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (2) , 760-781
Open AccessGlobal Co-occurrence Patterns of Cancer and Cardiovascular Disease: A Comprehensive Analysis Based on the Global Burden of Disease Study 2021
Introduction: Cardiovascular disease (CVD) and neoplasms are the two leading causes of death worldwide. Previous research has predominantly addressed these conditions separately or focused on specific regions. We aimed to characterize the global co-occurrence pattern of CVD and neoplasms from spatial and temporal perspectives and identify corresponding risk factors across different epidemiological contexts. Material and methods: Using GBD 2021 data, we extracted age-standardized disability-adjusted life years (DALYs) rates of CVD and neoplasms and modifiable risk factor exposure from 204 countries and territories (1990-2021). We identified four epidemiological patterns: low-burden, neoplasms-dominant, CVD-dominant, and dual-burden regions. We calculated population attributable fractions (PAF) and integrated machine learning with SHAP values to distinguish intervention priorities. Average annual percentage changes (AAPC) evaluated temporal trends. Results: Each pattern comprised 50-52 countries. Spatial distribution overlapped with socioeconomic development stages and risk factor exposure. Temporal analysis revealed widening global inequality: low-burden regions achieved 3-4% annual reductions while dual-burden regions experienced increasing burden, creating a 5.8 percentage point gap. High systolic blood pressure was the universal dominant CVD risk factor, accounting for 49.7% of global burden (49.2-52.4% across patterns). For neoplasms, smoking contributed 18.5% globally but varied dramatically by pattern (10.4-23.4%). Modifiable risk factors' specific combinations greatly influenced global disparities. Conclusions: The co-occurrence of CVD and neoplasms represents interconnected manifestations of different epidemiological transition stages, with concerning divergence between regions. Interventions targeting hypertension control and tobacco cessation, combined with pattern-specific strategies, can fundamentally reduce global disease burden.
- 24 October 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (3) , 104422
Global assessment of atherosclerotic cardiovascular disease quality of care index in adults aged ≥60 years
- 24 October 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (3) , 104422
Global assessment of atherosclerotic cardiovascular disease quality of care index in adults aged ≥60 years
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10311-10312
Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer [Corrigendum]
Corrigendum for the article Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer
- 1 July 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10311-10312
Open AccessSystemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer [Corrigendum]
Corrigendum for the article Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 2585-2596
A Prospective Study of the Correlation Between Time in Range and Incidence of Diabetic Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
Purpose: To investigate the correlation between time in range (TIR) and the risk of cardiovascular autonomic neuropathy (CAN) development in patients with Type 2 diabetes mellitus (T2DM). Patients and Methods: This prospective cohort study enrolled patients with type 2 diabetes mellitus (T2DM) hospitalized and followed at the Department of Endocrinology, Hefei Hospital of Anhui Medical University, between September 2020 and July 2024. All participants underwent standardized cardiovascular autonomic neuropathy (CAN) assessment via the Ewing test, and time in range (TIR) was derived from baseline continuous glucose monitoring (CGM) data. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CAN incidence, adjusted for relevant covariates. Results: Over a median follow-up of 25.0 months, 123 of 196 participants (62.8%) were diagnosed with CAN. The CAN group exhibited longer diabetes duration, lower time in range (TIR) and body mass index (BMI), higher time above range (TAR), mean glucose (MG), urinary albumin-to-creatinine ratio (UACR), and higher insulin use rates. Participants with low TIR were older, had longer diabetes duration, and displayed: 1. Higher fasting plasma glucose (FPG), HbA1c, and LDL-C levels; 2. Elevated glycemic variability (MAGE, CV, LAGE, SD, MG, TAR) via continuous glucose monitoring (CGM); 3. Greater likelihood of insulin therapy. All differences were statistically significant (P < 0.05). Multivariable Cox regression analyses, adjusted for key covariates (eg, age, HbA1c, insulin use), demonstrated an inverse association between TIR and CAN incidence. Conclusion: Lower TIR is an independent risk factor for CAN in T2DM patients, with higher TIR levels associated with reduced CAN risk (P < 0.05).
- 1 July 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 2585-2596
Open AccessA Prospective Study of the Correlation Between Time in Range and Incidence of Diabetic Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
Purpose: To investigate the correlation between time in range (TIR) and the risk of cardiovascular autonomic neuropathy (CAN) development in patients with Type 2 diabetes mellitus (T2DM). Patients and Methods: This prospective cohort study enrolled patients with type 2 diabetes mellitus (T2DM) hospitalized and followed at the Department of Endocrinology, Hefei Hospital of Anhui Medical University, between September 2020 and July 2024. All participants underwent standardized cardiovascular autonomic neuropathy (CAN) assessment via the Ewing test, and time in range (TIR) was derived from baseline continuous glucose monitoring (CGM) data. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CAN incidence, adjusted for relevant covariates. Results: Over a median follow-up of 25.0 months, 123 of 196 participants (62.8%) were diagnosed with CAN. The CAN group exhibited longer diabetes duration, lower time in range (TIR) and body mass index (BMI), higher time above range (TAR), mean glucose (MG), urinary albumin-to-creatinine ratio (UACR), and higher insulin use rates. Participants with low TIR were older, had longer diabetes duration, and displayed: 1. Higher fasting plasma glucose (FPG), HbA1c, and LDL-C levels; 2. Elevated glycemic variability (MAGE, CV, LAGE, SD, MG, TAR) via continuous glucose monitoring (CGM); 3. Greater likelihood of insulin therapy. All differences were statistically significant (P < 0.05). Multivariable Cox regression analyses, adjusted for key covariates (eg, age, HbA1c, insulin use), demonstrated an inverse association between TIR and CAN incidence. Conclusion: Lower TIR is an independent risk factor for CAN in T2DM patients, with higher TIR levels associated with reduced CAN risk (P < 0.05).
- Open Access
- 1 March 2025
- Published by Springer Nature in Endocrine
- Vol. 88 (2) , 650-659
Importance of assessing erectile dysfunction in patients with type 2 diabetes mellitus based on glucose fluctuation: a Cross-Sectional study
Purpose To investigate the relationship between glucose fluctuation and erectile dysfunction (ED) in patients with type 2 diabetes mellitus (T2DM). Methods This cross-sectional study included 317 male patients with T2DM. Participants were categorized into non-ED group (76 cases) and ED group (241 cases) based on International Index of Erectile Function-5 (IIEF-5) scores. Patients were additionally segmented into quartiles based on time in range (TIR). Demographic and laboratory data were collected, and glucose fluctuation indicators were ascertained using flash glucose monitoring. Results The ED group exhibited significantly lower TIR and IIEF-5 scores compared to the non-ED group (P < 0.05). An increase in TIR levels corresponded with higher IIEF-5 scores and a significant reduction in ED incidence (P < 0.05). Spearman’s correlation analysis indicated a positive correlation between IIEF-5 scores and TIR (r = 0.48, P < 0.01). Restricted cubic spline analysis revealed a negative linear association between TIR and ED (P for linearity <0.05). Multivariate logistic regression analysis, after adjusting for confounding factors, confirmed that low TIR is an independent risk factor for ED (P < 0.05). Conclusion Glucose fluctuation in T2DM patients correlate with ED, with low TIR being independently and positively associated with ED incidence, suggesting it may be a significant risk factor for ED in patients with T2DM.
- 1 March 2025
- Published by Springer Nature in Endocrine
- Vol. 88 (2) , 650-659
Open AccessImportance of assessing erectile dysfunction in patients with type 2 diabetes mellitus based on glucose fluctuation: a Cross-Sectional study
Purpose To investigate the relationship between glucose fluctuation and erectile dysfunction (ED) in patients with type 2 diabetes mellitus (T2DM). Methods This cross-sectional study included 317 male patients with T2DM. Participants were categorized into non-ED group (76 cases) and ED group (241 cases) based on International Index of Erectile Function-5 (IIEF-5) scores. Patients were additionally segmented into quartiles based on time in range (TIR). Demographic and laboratory data were collected, and glucose fluctuation indicators were ascertained using flash glucose monitoring. Results The ED group exhibited significantly lower TIR and IIEF-5 scores compared to the non-ED group (P < 0.05). An increase in TIR levels corresponded with higher IIEF-5 scores and a significant reduction in ED incidence (P < 0.05). Spearman’s correlation analysis indicated a positive correlation between IIEF-5 scores and TIR (r = 0.48, P < 0.01). Restricted cubic spline analysis revealed a negative linear association between TIR and ED (P for linearity <0.05). Multivariate logistic regression analysis, after adjusting for confounding factors, confirmed that low TIR is an independent risk factor for ED (P < 0.05). Conclusion Glucose fluctuation in T2DM patients correlate with ED, with low TIR being independently and positively associated with ED incidence, suggesting it may be a significant risk factor for ED in patients with T2DM.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8531-8541
Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer
Purpose: This research sought to evaluate the clinical value of systemic immune-inflammation index and systemic inflammation response index in predicting the response to radioactive iodine (RAI) therapy in individuals diagnosed with differentiated thyroid cancer. Patients and Methods: This retrospective study included 406 patients with differentiated thyroid cancer who received initial RAI therapy and follow-up from December 2019 to December 2023. Patients were divided into two groups based on imaging and serum indicators to evaluate the response to radioactive iodine treatment: the ER group (excellent response) and the non-ER group (suboptimal response). Systemic immune-inflammation index and systemic inflammation response index were calculated based on peripheral blood cell counts before treatment. Multivariable logistic regression analysis was used to assess the independent associations of these indices with the therapeutic response to radioiodine treatment. Receiver operating characteristic (ROC) curves were graphed and the area under the curve (AUC) was calculated to evaluate their predictive ability. Results: Compared to the ER group, patients in the non-ER group had significantly elevated systemic immune-inflammation index and systemic inflammation response index levels (p < 0.001). After adjusting for confounding factors, there was a significant association between these indices and the response to radioactive iodine treatment in patients with differentiated thyroid cancer. The optimal cutoff values for predicting the response to RAI treatment were 668.91 for systemic immune-inflammation index (AUC=0.692, sensitivity 58.2%, specificity 73.1%, 95% CI: 0.639– 0.745, p < 0.001) and 0.47 for systemic inflammation response index (AUC=0.664, sensitivity 85.6%, specificity 42.7%, 95% CI: 0.612– 0.717, p < 0.001). Conclusion: Systemic immune-inflammation index and systemic inflammation response index could be valuable for predicting the response to RAI treatment in individuals diagnosed with differentiated thyroid cancer. Further research is needed to explore their practical utility, and these novel inflammation markers could serve as adjunct tools in clinical practice.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8531-8541
Open AccessSystemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer
Purpose: This research sought to evaluate the clinical value of systemic immune-inflammation index and systemic inflammation response index in predicting the response to radioactive iodine (RAI) therapy in individuals diagnosed with differentiated thyroid cancer. Patients and Methods: This retrospective study included 406 patients with differentiated thyroid cancer who received initial RAI therapy and follow-up from December 2019 to December 2023. Patients were divided into two groups based on imaging and serum indicators to evaluate the response to radioactive iodine treatment: the ER group (excellent response) and the non-ER group (suboptimal response). Systemic immune-inflammation index and systemic inflammation response index were calculated based on peripheral blood cell counts before treatment. Multivariable logistic regression analysis was used to assess the independent associations of these indices with the therapeutic response to radioiodine treatment. Receiver operating characteristic (ROC) curves were graphed and the area under the curve (AUC) was calculated to evaluate their predictive ability. Results: Compared to the ER group, patients in the non-ER group had significantly elevated systemic immune-inflammation index and systemic inflammation response index levels (p < 0.001). After adjusting for confounding factors, there was a significant association between these indices and the response to radioactive iodine treatment in patients with differentiated thyroid cancer. The optimal cutoff values for predicting the response to RAI treatment were 668.91 for systemic immune-inflammation index (AUC=0.692, sensitivity 58.2%, specificity 73.1%, 95% CI: 0.639– 0.745, p < 0.001) and 0.47 for systemic inflammation response index (AUC=0.664, sensitivity 85.6%, specificity 42.7%, 95% CI: 0.612– 0.717, p < 0.001). Conclusion: Systemic immune-inflammation index and systemic inflammation response index could be valuable for predicting the response to RAI treatment in individuals diagnosed with differentiated thyroid cancer. Further research is needed to explore their practical utility, and these novel inflammation markers could serve as adjunct tools in clinical practice.
- Open Access
- 26 October 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
Time trends and advances in the management of global, regional, and national diabetes in adolescents and young adults aged 10–24 years, 1990–2021: analysis for the global burden of disease study 2021
Estimation of global diabetes burden in adolescents and young adults (10–24 years) from 1990 to 2021. Data were extracted from the 2021 Global Burden of Disease Study. Joinpoint regression analysis was employed to examine trends over the past 30 years, frontier analysis identified regions with potential for improvement, and the slope index of inequality and the relative concentration index were used to assess health inequalities. From 1990 to 2021, the age-standardized prevalence rates (ASPR) and age-standardized disability-adjusted life years rates (ASDR) of diabetes in adolescents and young adults increased globally, while age-standardized death rates (ASMR) remained stable. Oceania bore the highest burden regionally, East Asia experienced the fastest rise in ASPR and ASDR, and High-income Asia Pacific saw the most significant decrease in ASMR. Among 204 countries, Marshall Island and Hait reported the highest ASPR, ASDR, and ASMR in 2021. Health inequality analysis confirmed that the burden was concentrated in countries with lower Socio-Demographic Index (SDI). Frontier analysis showed that ASMR and ASDR were negatively correlated with SDI, with Yemen and Honduras, which have lower socio-demographic indices, exhibiting more smaller overall differences from frontier boundaries. The analysis revealed a sharp increase in the global ASPR and ASDR of diabetes in adolescents and young adults. Additionally, the disease burden is typically concentrated in countries with lower SDI, highlighting an urgent need for governments to develop flexible health policies to mitigate the escalating threat of diabetes in this demographic.
- 26 October 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
Open AccessTime trends and advances in the management of global, regional, and national diabetes in adolescents and young adults aged 10–24 years, 1990–2021: analysis for the global burden of disease study 2021
Estimation of global diabetes burden in adolescents and young adults (10–24 years) from 1990 to 2021. Data were extracted from the 2021 Global Burden of Disease Study. Joinpoint regression analysis was employed to examine trends over the past 30 years, frontier analysis identified regions with potential for improvement, and the slope index of inequality and the relative concentration index were used to assess health inequalities. From 1990 to 2021, the age-standardized prevalence rates (ASPR) and age-standardized disability-adjusted life years rates (ASDR) of diabetes in adolescents and young adults increased globally, while age-standardized death rates (ASMR) remained stable. Oceania bore the highest burden regionally, East Asia experienced the fastest rise in ASPR and ASDR, and High-income Asia Pacific saw the most significant decrease in ASMR. Among 204 countries, Marshall Island and Hait reported the highest ASPR, ASDR, and ASMR in 2021. Health inequality analysis confirmed that the burden was concentrated in countries with lower Socio-Demographic Index (SDI). Frontier analysis showed that ASMR and ASDR were negatively correlated with SDI, with Yemen and Honduras, which have lower socio-demographic indices, exhibiting more smaller overall differences from frontier boundaries. The analysis revealed a sharp increase in the global ASPR and ASDR of diabetes in adolescents and young adults. Additionally, the disease burden is typically concentrated in countries with lower SDI, highlighting an urgent need for governments to develop flexible health policies to mitigate the escalating threat of diabetes in this demographic.
- Open Access
- 16 June 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-11
J-shaped relationship between stress hyperglycemia ratio and 90-day and 180-day mortality in patients with a first diagnosis of acute myocardial infarction: analysis of the MIMIC-IV database
Aims: The Stress Hyperglycemia Ratio (SHR) potently predicts adverse outcomes in patients with cardiovascular and cerebrovascular diseases. However, the relationship between SHR and short-term mortality risk in patients with a first diagnosis of acute myocardial infarction (AMI) remains contentious. This study sought to understand better the relationship between SHR and short-term mortality risk in patients with a first diagnosis of AMI. Methods: We conducted a cohort study using data from 1961 patients with a first diagnosis of AMI from the MIMIC-IV (version 2.2) database. Patients were divided into three groups based on SHR tertiles. The Cox proportional hazards model and a two-segmented Cox proportional hazards model were used to elucidate the nonlinear relationship between SHR in patients with a first diagnosis of AMI and mortality. Results: Of the surveyed population, 175 patients (8.92%) died within 90 days, and 210 patients (10.71%) died within 180 days. After multivariate adjustments, elevated SHR levels were significantly and non-linearly associated with a higher risk of 90-day and 180-day mortality in patients with a first diagnosis of AMI, showing a J-shaped correlation with an inflection point at 0.9. Compared to participants with SHR levels below the inflection point, those with higher SHR levels had a fivefold increased risk of 90-day mortality (hazard ratio [HR] 5.74; 95% confidence interval [CI] 3.19, 10.33) and a fourfold increased risk of 180-day mortality (HR 4.56; 95% CI 2.62, 7.95). In the subgroup analysis, patients with pre-diabetes mellitus (pre-DM) and higher SHR levels had increased 90-day (HR 6.90; 95% CI 1.98, 24.02) and 180-day mortality risks (HR 5.30; 95% CI 1.96, 14.27). Conclusion: In patients with a first diagnosis of AMI, there is a J-shaped correlation between SHR and 90-day and 180-day mortality, with an adverse prognostic inflection point of SHR at 0.9.
- 16 June 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-11
Open AccessJ-shaped relationship between stress hyperglycemia ratio and 90-day and 180-day mortality in patients with a first diagnosis of acute myocardial infarction: analysis of the MIMIC-IV database
Aims: The Stress Hyperglycemia Ratio (SHR) potently predicts adverse outcomes in patients with cardiovascular and cerebrovascular diseases. However, the relationship between SHR and short-term mortality risk in patients with a first diagnosis of acute myocardial infarction (AMI) remains contentious. This study sought to understand better the relationship between SHR and short-term mortality risk in patients with a first diagnosis of AMI. Methods: We conducted a cohort study using data from 1961 patients with a first diagnosis of AMI from the MIMIC-IV (version 2.2) database. Patients were divided into three groups based on SHR tertiles. The Cox proportional hazards model and a two-segmented Cox proportional hazards model were used to elucidate the nonlinear relationship between SHR in patients with a first diagnosis of AMI and mortality. Results: Of the surveyed population, 175 patients (8.92%) died within 90 days, and 210 patients (10.71%) died within 180 days. After multivariate adjustments, elevated SHR levels were significantly and non-linearly associated with a higher risk of 90-day and 180-day mortality in patients with a first diagnosis of AMI, showing a J-shaped correlation with an inflection point at 0.9. Compared to participants with SHR levels below the inflection point, those with higher SHR levels had a fivefold increased risk of 90-day mortality (hazard ratio [HR] 5.74; 95% confidence interval [CI] 3.19, 10.33) and a fourfold increased risk of 180-day mortality (HR 4.56; 95% CI 2.62, 7.95). In the subgroup analysis, patients with pre-diabetes mellitus (pre-DM) and higher SHR levels had increased 90-day (HR 6.90; 95% CI 1.98, 24.02) and 180-day mortality risks (HR 5.30; 95% CI 1.96, 14.27). Conclusion: In patients with a first diagnosis of AMI, there is a J-shaped correlation between SHR and 90-day and 180-day mortality, with an adverse prognostic inflection point of SHR at 0.9.